11
Participants
Start Date
January 24, 2018
Primary Completion Date
April 8, 2024
Study Completion Date
May 8, 2024
Tadekinig alfa
Open label, 26 weeks on Tadekinig alfa treatment.
Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Children Hospital of Philadelphia, Philadelphia
Children's Healthcare of Atlanta at Egleston, Atlanta
Shands Children's Hospital, Gainsville
Cincinnati Children's Hospital Medical Center, Cincinnati
Texas Children's Hospital _ Baylor College of Medicine, Houston
Universitätsklinikum Freiburg, Centrum für Chronische Immundefizienz (CCI) - Paediatric Unit, Freiburg im Breisgau
UCSD _ Department of Pediatrics / Rady Children's Hospital, La Jolla
Boston Children's Hospital, Boston
The Hospital for Sick Children, Toronto
CHU Sainte-Justine, Montreal
Lead Sponsor
AB2 Bio Ltd.
INDUSTRY